Monday, June 2, 2003 - including Plenary Sessions

OncoLink Editor-in-Chief Dr. James Metz and OncoLink Managing Editor Maggie Hampshire

A Phase III Trial comparing Gemcitabine plus Cisplatin vs. Gemcitabine alone in advanced pancreatic cancer Presenter: V. HeinemannPresenter's Affiliation: University of Munich; Munich, GermanyType of Session: ScientificBackground Pancreatic cancer has a very poor prognosis. Most patients are diagnosed in the metastatic stage. Median survival is 3-4...
A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis Presenter: R. PatchellPresenter's Affiliation: University of KentuckyType of Session: PlenaryBackground Cord compression by metastatic disease is a large problem in cancers that has the propensity to spread to bone. As prostate cancer, breast...
Age as a continuous variable in predicting outcome for neuroblastoma patients with metastatic disease: Impact of tumor biological features Presenter: R. GeorgePresenter's Affiliation: COGType of Session: ScientificBackground Infants (age 0-12 months) with stage D disease, with single copy n-myc and hyperdiploidy tumors have an excellent prognosis (84% 4 yr EFS vs. 46% 4 year EFS in...
Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs. radiochemotherapy in patients with locally advanced esophageal cancer) Presenter: F BonnetainPresenter's Affiliation: Federation Francophone de Cancerologie DigestiveType of Session: ScientificBackground FFCD 9102 was a randomized trial comparing chemoradiation + surgery versus chemoRT alone for locally advanced, but...
Docetaxel and cisplatin versus M-VAC in advanced urothelial carcinoma: A multicenter, randomized, phase III study conducted by the Hellenic Cooperative Oncology Group Presenter: A. BamiasPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground Urothelial carcinoma is a relatively common cancer with a significant risk of disease progression and spread. Untreated...
Docetaxel, Cisplatin, 5-Fluorouracil compare to Cisplatin and 5-fluorouracil for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325) Presenter: J. A. AjaniPresenter's Affiliation: MD Anderson Cancer Center; Houston , TXType of Session: ScientificBackground Gastric cancer is the 2nd most frequent world wide malignancy and is the 2nd most frequent cause of cancer deaths world wide. ...
Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer Presenter: L PusztaiPresenter's Affiliation: MD Anderson Cancer Center, TexasType of Session: PlenaryBackground Multiple different chemotherapy regimens are used in the treatment of breast cancer. One common regimen involves neoadjuvant paclitaxel +...
Gemcitabine vs. GEMOX (gemcitabine + oxaliplatin) in non-resectable pancreatic adenocarcinoma: Interim results of GERCOR/GISCAD intergroup Phase III Presenter: C. LouvetPresenter's Affiliation: Hospital St. Antoine; Paris, FranceType of Session: ScientificBackground Gemcitabine 1g/m2 in a 30 min infusion remains the reference regimen for non-resectable pancreatic cancer. Oxaliplatin and...
Low dose bleomycin every three weeks with cisplatin and etoposide results in excellent event free survival and survival in children and adolescents with gonadal malignant germ cell tumors (MGCT) A POG/CCG Study Presenter: T.A. OlsonPresenter's Affiliation: Children's Oncology GroupType of Session: ScientificBackground Bleomycin is a standard component of multi-drug chemotherapy for MGCT. It is the least effective single agent in this regimen. Concern...
MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC) Presenter: M. KriegePresenter's Affiliation: University Medical Center RotterdamType of Session: PlenaryBackground Women at high genetic or familial risk for breast cancer undergo careful surveillance. The value of screening in these women is...
Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial (the MAGIC trial, ISRCTN 9379397) Presenter: W. AllumPresenter's Affiliation: Epsum General Hospital; Surrey, UKType of Session: ScientificBackground The combination of Epirubicin, Cisplatin and infusional 5-FU (ECF) has demonstrated increased RR and statistically significant benefit...
Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) Presenter: P LoriganPresenter's Affiliation: Manchester Lung Cancer GroupType of Session: ScientificBackground Although SCLC is chemosensitive, it is associated with low rates of cure. Several previous phase II and III trials have attempted to...
Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: chemoradiation with and without surgery Presenter: M StahlPresenter's Affiliation: German Oesophageal Cancer Study GroupType of Session: ScientificBackground Treatment of locally advanced esophageal cancer remains difficult. Treatment with surgery alone results in overall survival (OS) of...
Results from a phase II trial of conformal radiation therapy (CRT)for pediatric patients with localized ependymoma and quantification of radiation-related CNS effects Presenter: T.E. MerchantPresenter's Affiliation: St. Jude Children's Research HospitalType of Session: ScientificBackground Radiation therapy (RT) following maximal resection is the standard treatment for localized ependymoma in children. In very...
Results of a randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) Presenter: T. LeChevalierPresenter's Affiliation: Institut Gustave RoussyType of Session: PlenaryBackground 1.2 million cases of NSCLC are diagnosed yearly worldwide. 30% of these are resectable but local therapy is not consistently curative. ...
Surgical variables impact bladder cancer outcomes: A cooperative group report Presenter: H. HerrPresenter's Affiliation: Southwestern Oncology Group, IntergroupType of Session: ScientificBackground The use of neoadjuvant MVAC (methotrexate, vinblastine, adriamycin, cisplatin) followed by cystectomy was shown to be superior...
Surveillance of "high-risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial Presenter: C. K. KuhlPresenter's Affiliation: University of Bonn, GermanyType of Session: PlenaryBackground Hereditary breast cancer is associated with a high lifetime risk of developing breast cancer and a relatively early age of onset. As a...
Whole Abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group Presenter: M.E. RandallPresenter's Affiliation: GOGType of Session: PlenaryBackground Endometrial cancer is the most common gynecologic cancer diagnosed Treatment for stage III endometrial cancer has ranged from no treatment to chemotherapy alone to...